Original Report: Patient-Oriented, Translational Research
Impact of Ergocalciferol Treatment of Vitamin D Deficiency on Serum Parathyroid Hormone Concentrations in Chronic Kidney DiseaseZisman A.L. · Hristova M. · Ho L.T. · Sprague S.M.
Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, Ill., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Vitamin D deficiency is highly prevalent and associated with secondary hyperparathyroidism in patients with chronic kidney disease (CKD). The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend treatment of vitamin D deficiency starting with CKD stage 3, though no data are available showing an impact on serum parathyroid hormone (PTH) concentrations. The goal of this analysis, therefore, was to determine the effect of ergocalciferol treatment on plasma PTH concentrations in vitamin D-deficient patients with stage 3 and stage 4 CKD. Methods: A prospective, nonrandomized observational analysis was conducted in an academic community hospital CKD clinic. Fifty-two patients with stage 3 or stage 4 CKD with vitamin D deficiency and elevated PTH concentrations received ergocalciferol dosed per a modified K/DOQI guidelines protocol and adjusted every 3 months. Serum PTH, 25-vitamin D, 1,25-vitamin D, calcium, phosphorus, and albumin levels were drawn at initiation of therapy and repeated every 3 months. Results: The mean 25-vitamin D levels normalized in patients with stage 3 and 4 CKD, with values of 31.6 ± 2.2 ng/ml (78.8 ± 5.49 nmol/l) and 35.4 ± 1.9 ng/ml (88.4 ± 4.74 nmol/l), respectively (p < 0.0001). A median decrease in PTH concentrations of 13.1 and 2.0% was noted in patients with stage 3 and stage 4 CKD, respectively (p = 0.041, p = nonsignificant). Conclusions: Ergocalciferol therapy is a reasonable initial therapy for vitamin D deficiency associated with elevated PTH levels in stage 3 CKD. It does not appear to have equivalent benefits in stage 4 CKD.
© 2007 S. Karger AG, Basel
DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(suppl 6):1689–1696.
- Chapuy MC, Preziosi P, Maaner M, et al: Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7:439–443.
- Malabanan A, Veronikis IE, Holick MF: Redefining vitamin D insufficiency. Lancet 1998;351:805–806.
- Tangpricha V, Pearce EN, Chen TC, Holick MF: Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002;112:659–662.
- Thomas MK, Lloyd-Jones DM, Thadhani RI, et al: Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777–783.
- LaClair RE, Hellman RN, Karp SL, et al: Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005;45:1026–1033.
- Eastwood JB, de Wardener HE, Gray RW, Lemann JL Jr: Normal plasma-1,25-(OH)2-vitamin-D concentrations in nutritional osteomalacia. Lancet 1979;314:1377–1378.
- Adams JS, Clemens TL, Parrish JA, Holick MF: Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med 1982;306:722–725.
- Lucas PA, Brown RC, Woodhead JS, Colesi GA: 1,25-Dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: effect of simultaneous protein and phosphorus restriction. Clin Nephrol 1986;25:7–10.
- Sherrard DJ, Hercz G, Pei Y, et al: The spectrum of bone disease in end-stage renal failure – an evolving disorder. Kidney Int 1993;43:436–442.
- Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995;333:166–174.
- De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002;13:2762–2769.
- Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;56(suppl 73):S14–S19.
- Felsenfeld AJ, Rodriguez M: Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 1999;10:878–890.
- Reynolds JL, Joannides AJ, Skepper JN, et al: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857–2867.
- Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138.
- Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607–617.
- Stehman-Breen CO, Sherrard DJ, Alem AM, et al: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:2200–2205.
National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42(suppl 3):S1–S201.
- Wesson LG: Homeostasis of phosphate revisited. Nephron 1997;77:249–266.
- Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6:162–169.
- Pitts TO, Piraino BH, Mitro R, et al: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988;67:876–881.
- Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992;19:532–539.
- Coburn JW, Maung HM, Elangovan L, et al: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877–890.
- Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D: Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38(suppl 5):S51–S56.
- Coyne D, Acharya M, Qiu P, et al: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006;47:263–276.
- Holick MF, Matsuoka LY, Wortsman J: Age, vitamin D, and solar ultraviolet. Lancet 1989;334:1104–1105.
Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune disease, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(suppl 6):1678S–1688S.
- Lee S, Clark SA, Gill RK, Christakos S: 1,25-Dihydroxyvitamin D3 and pancreatic B-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 1994;134:1602–1610.
Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;70:2861–2869.
- Hypponen E, Laara E, Jarvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500–1503.
- Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG: Vitamin D intake is inversely associated with rheumatoid arthritis. Arthritis Rheum 2004;50:72–77.
- Li Y, Kong J, Wei M, Chen ZF, Liu S, Cao LP: 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229–238.
- Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet 1998;352:709–710.
- Zitterman A, Schleithoff SS, Tenderich G, Berthold HK, Korger R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105–112.
- Black PN, Scragg R: Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Chest 2005;128:3792–3798.
- Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF: Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998;7:391–395.
- Tangpricha V, Flanagan JN, Whitlatch LW, et al: 25-Hydroxyvitamin D 1α hydroxylase in normal and malignant colon tissue. Lancet 2001;357:1673–1674.
- Townsend K, Banwell CM, Guy M, et al: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 2005;11:3579–3586.
Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 2005;289:F8–F28.
- Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS, Hewison M: Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 2005;97:103–109.
- Teng M, Wolf M, Ofsthun MN, et al: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115–1125.
- Pattanaungkul S, Riggs BL, Yergey Al, Vieira NE, O’Fallon WM, Khosla S: Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in young vs. elderly women: evidence of age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab 2000;85:4023–4027.
Weaver CM, Fleet JC: Vitamin D requirements: current and future. Am J Clin Nutr 2004;80(suppl 6):1735S–1739S.
- Vieth R, Chan PC, MacFarlane GD: Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288–294.
- Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.